Kidney Transplant Rejection - Pipeline Review, H2 2017

  • ID: 4418948
  • Report
  • 171 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • Corline Biomedical AB
  • GlaxoSmithKline Plc
  • Kyowa Hakko Kirin Co Ltd
  • Opsona Therapeutics Ltd
  • MORE
Kidney Transplant Rejection - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 11, 9, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • Corline Biomedical AB
  • GlaxoSmithKline Plc
  • Kyowa Hakko Kirin Co Ltd
  • Opsona Therapeutics Ltd
  • MORE
Introduction

Kidney Transplant Rejection - Overview

Kidney Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Transplant Rejection - Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

Amgen Inc

Angion Biomedica Corp

Apellis Pharmaceuticals Inc

Astellas Pharma Inc

Biogen Inc

Bioverativ Inc

Catalyst Biosciences Inc

Corline Biomedical AB

CSL Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Hansa Medical AB

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

Magnus Life Ltd

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Ltd

Pharmicell Co Ltd

Prolong Pharmaceuticals LLC

Quark Pharmaceuticals Inc

Shire Plc

Tiziana Life Sciences Plc

Kidney Transplant Rejection - Drug Profiles

2C-10 - Drug Profile

ambrisentan - Drug Profile

AMY-101 - Drug Profile

APL-2 - Drug Profile

AS-2521780 - Drug Profile

ASP-0028 - Drug Profile

basiliximab biobetter - Drug Profile

BB-3 - Drug Profile

belimumab - Drug Profile

BIVV-009 - Drug Profile

bleselumab - Drug Profile

C1 esterase inhibitor (human) - Drug Profile

C1 esterase inhibitor (human) - Drug Profile

carfilzomib - Drug Profile

CB-2782 - Drug Profile

Cellgram for Kidney Transplant Rejection - Drug Profile

Cellular Immunotherapy for Kidney Transplantation - Drug Profile

Cellular Immunotherapy for Kidney Transplantation - Drug Profile

Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile

CFZ-533 - Drug Profile

eculizumab - Drug Profile

foralumab - Drug Profile

FR-104 - Drug Profile

FX-06 - Drug Profile

GS-492429 - Drug Profile

GSK-1070806 - Drug Profile

HBI-002 - Drug Profile

HBI-137 - Drug Profile

lefluonomide - Drug Profile

MDR-101 - Drug Profile

MDR-102 - Drug Profile

MDR-103 - Drug Profile

MDR-104 - Drug Profile

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile

MRX-109 - Drug Profile

OPN-305 - Drug Profile

QPI-1002 - Drug Profile

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile

Renaparin - Drug Profile

rituximab - Drug Profile

Sanguinate - Drug Profile

tacrolimus - Drug Profile

Ti-061 - Drug Profile

tiomolibdate diammonium - Drug Profile

Triplex - Drug Profile

Vaccine for Kidney Transplant Rejection, Cytomegalovirus Infections and Renal Failure - Drug Profile

Kidney Transplant Rejection - Dormant Projects

Kidney Transplant Rejection - Discontinued Products

Kidney Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Kidney Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H2

Kidney Transplant Rejection - Pipeline by Amgen Inc, H2

Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp, H2

Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc, H2

Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H2

Kidney Transplant Rejection - Pipeline by Biogen Inc, H2

Kidney Transplant Rejection - Pipeline by Bioverativ Inc, H2

Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc, H2

Kidney Transplant Rejection - Pipeline by Corline Biomedical AB, H2

Kidney Transplant Rejection - Pipeline by CSL Ltd, H2

Kidney Transplant Rejection - Pipeline by Gilead Sciences Inc, H2

Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H2

Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H2

Kidney Transplant Rejection - Pipeline by Johnson & Johnson, H2

Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd, H2

Kidney Transplant Rejection - Pipeline by Magnus Life Ltd, H2

Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H2

Kidney Transplant Rejection - Pipeline by Novartis AG, H2

Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd, H2

Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H2

Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC, H2

Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H2

Kidney Transplant Rejection - Pipeline by Shire Plc, H2

Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc, H2

Kidney Transplant Rejection - Dormant Projects, H2

Kidney Transplant Rejection - Discontinued Products, H2

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexion Pharmaceuticals Inc
  • Amgen Inc
  • Angion Biomedica Corp
  • Apellis Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biogen Inc
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • Corline Biomedical AB
  • CSL Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hansa Medical AB
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co Ltd
  • Magnus Life Ltd
  • Noorik Biopharmaceuticals AG
  • Novartis AG
  • Opsona Therapeutics Ltd
  • Pharmicell Co Ltd
  • Prolong Pharmaceuticals LLC
  • Quark Pharmaceuticals Inc
  • Shire Plc
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll